2. Search Result
Search Result
Results for "

E3 ligase Ligand 3

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103597
    Thalidomide-O-COOH
    1 Publications Verification

    Cereblon Ligand 3; E3 ligase Ligand 3

    		 Ligands for E3 Ligase Others
    Thalidomide-O-COOH (Cereblon ligand 3) is the Thalidomide-based Cereblon ligand used in the recruitment of CRBN protein. Thalidomide-O-COOH (Cereblon ligand 3) can be connected to the ligand for protein by a linker to form PROTACs .
    Thalidomide-O-COOH
  • HY-125905
    VH032-cyclopropane-F
    1 Publications Verification

    VHL Ligand 3; E3 ligase Ligand 19

    		 Ligands for E3 Ligase Cancer
    VH032-cyclopropane-F is the VH032-based VHL ligand. VH032-cyclopropane-F can be connected to the ligand for protein (e.g., SMARCA BD ligand) by a linker to form PROTACs (e.g., PROTAC 1). PROTAC 1 is a partial degrader of SMARCA2 and SMARCA4 .
    VH032-cyclopropane-F
  • HY-172359
    PROTAC HDAC6 degrader 4

    		PROTACs HDAC Cancer
    PROTAC HDAC6 degrader 4 (Compound 17c) is the PROTAC degrader for HDAC6 with a DC50 of 14 nM. PROTAC HDAC6 degrader 4 exhibits inhibitory activit against HDAC1, HDAC2, HDAC3 and HDAC6 with IC50s of 2.2, 2.37, 0.61 and 0.295 μM, respectively . (Pink: ligand for target protein HDAC6 ligand-3 (HY-172360); Black: linker (HY-138387); Blue: ligand for cereblon E3 ligase (HY-W093272))
    PROTAC HDAC6 degrader 4
  • HY-162875
    PROTAC BRD4 Degrader-27

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-27 (compound 6b) is a PROTAC that selectively targets BRD4 (rather than BRD2/BRD3) and can also inhibit the expression of KLF5 transcription factor and exert anti-cancer activity. PROTAC BRD4 Degrader-27 is composed of E3 ubiquitinase ligand Thalidomide-4-OH (HY-103596) (red part), PROTAC Linker γ-Aminobutyric acid (HY-N0067) (black part) and PROTAC target protein ligand PROTAC BRD4 ligand-3 (HY-162876) (blue part), of which the active control of the target protein ligand is Mivebresib (HY-100015), and the conjugate of E3 ubiquitin ligase ligand + Linker is Pomalidomide 4'-alkylC3-acid (HY-131875) [1] .
    PROTAC BRD4 Degrader-27
  • HY-170852
    QZ2135

    		PROTACs RET Cancer
    QZ2135 (compound 20) is a RET-targeted PROTAC degrader with in vivo antitumor properties in a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The degradation activities of QZ2135 targeting KIF5B-RET have DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C), respectively. QZ2135 is composed of a target protein ligand (red part) RET ligand-3 (HY-170853), an E3 ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC Linker (black part) 7-Iodohept-1-yne (HY-W587352), in which the target protein ligand + linker form a conjugate RET Ligand-Linker Conjugate-1 (HY-170854) .
    QZ2135
  • HY-159608
    PROTAC Cbl-b-IN-1

    		PROTACs Cancer
    PROTAC Cbl-b-IN-1 (compound 64) is a PROTAC targeting Cbl-b. PROTAC Cbl-b-IN-1 is composed of PROTAC target protein ligand Cbl-b-IN-21 (HY-159615), PROTAC Linker Cbz-Pip-2C-Pip-C-Pip (HY-159617) and E3 ubiquitin ligase ligand (3S) Lenalidomide-5-Br (HY-W797329), where the E3 ubiquitin ligase ligand + Linker conjugate is (3S) Lenalidomide-5-Pip-C-Pip-2C-Pip (HY-159618) [1] .
    PROTAC Cbl-b-IN-1
  • HY-162813
    PROTAC SMARCA2/4-degrader-25

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC SMARCA2/4-degrader-25 (compound 7d) is a PROTAC targeting SMARCA2/4. PROTAC SMARCA2/4-degrader-25 is composed of E3 ligase (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (HY-W998248) (blue part), PROTAC Linker (S)-2-Amino-3,3-dimethylbutanoic acid (HY-59140) (black part), and target protein ligand SMARCA2/4-ligand-3 (HY-162814) (red part). The conjugate of E3 ubiquitin ligase ligand + Linker is (S,R,S)-AHPC (HY-125845) [1] .
    PROTAC SMARCA2/4-degrader-25
  • HY-170978
    PROTAC CDK9 degrader-11

    		PROTACs CDK Cancer
    PROTAC CDK9 degrader-11 (Compound C3) is an orally active PROTAC degrader for CDK9 with DC50 of 1.09 nM. PROTAC CDK9 degrader-11 exhibits cytotoxicity in multi small cell lung cancer cell with IC50 of nanomolar levels. PROTAC CDK9 degrader-11 arrests cell cycle at G0/G1 phase, inhibits the cell invasion in DMS114 and DMS53 cell. PROTAC CDK9 degrader-11 exhibits antitumor efficacy in NCI-H446 xenograft mouse models .(Pink: ligand for target protein CDK9 ligand 3 (HY-170979); Black: linker; Blue: ligand for E3 ligase Cereblon E3 ligase Ligand 56 (HY-W247437))
    PROTAC CDK9 degrader-11

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: